KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Cash from Investing Activities (2016 - 2025)

Cvs Health (CVS) has disclosed Cash from Investing Activities for 17 consecutive years, with -$2.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 265.27% year-over-year to -$2.0 billion, compared with a TTM value of -$5.9 billion through Dec 2025, up 22.88%, and an annual FY2025 reading of -$5.9 billion, up 22.88% over the prior year.
  • Cash from Investing Activities was -$2.0 billion for Q4 2025 at Cvs Health, up from -$2.1 billion in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$119.0 million in Q4 2022 and bottomed at -$10.4 billion in Q2 2023.
  • Average Cash from Investing Activities over 5 years is -$2.2 billion, with a median of -$1.5 billion recorded in 2021.
  • The sharpest move saw Cash from Investing Activities skyrocketed 91.74% in 2022, then crashed 943.7% in 2023.
  • Year by year, Cash from Investing Activities stood at -$1.4 billion in 2021, then surged by 91.74% to -$119.0 million in 2022, then plummeted by 943.7% to -$1.2 billion in 2023, then skyrocketed by 55.96% to -$547.0 million in 2024, then tumbled by 265.27% to -$2.0 billion in 2025.
  • Business Quant data shows Cash from Investing Activities for CVS at -$2.0 billion in Q4 2025, -$2.1 billion in Q3 2025, and -$1.0 billion in Q2 2025.